摘要
目的:探究沙库巴曲缬沙坦对慢性心力衰竭(CHF)患者血管紧张素Ⅱ(AngⅡ)、醛固酮(ALD)、N末端B型利钠肽前体(NT-proBNP)水平及心功能的影响。方法:选取2021年1月—2023年1月荆州市第三人民医院收治的65例CHF患者为研究对象。根据随机抽签法将其分为对照组(32例)与观察组(33例)。对照组给予缬沙坦片,观察组给予沙库巴曲缬沙坦钠片。比较两组治疗前及治疗6个月后实验室指标、生活质量及心功能。结果:治疗6个月后,两组AngⅡ、ALD、NT-pro BNP水平均下降,观察组AngⅡ、ALD、NT-pro BNP水平均低于对照组,差异有统计学意义(P<0.05)。治疗6个月后,两组左心室射血分数(LVEF)升高,左心室收缩期内径(LVESD)及左心室舒张期内径(LVEDD)均降低,观察组LVEF显著高于对照组,LVESD、LVEDD显著低于对照组,差异有统计学意义(P<0.05)。治疗6个月后,两组身体、情绪及其他评分均下降,观察组身体、情绪及其他评分均低于对照组,差异有统计学意义(P<0.05)。结论:沙库巴曲缬沙坦治疗CHF患者,可降低AngⅡ、ALD、NT-proBNP水平,减轻心脏负荷,改善患者心功能,促进生活质量提高。
Objective:To investigate the effect of Sacubitril Valsartan on the levels of angiotensinⅡ(AngⅡ),aldosterone(ALD)and N-terminal pro-B-type natriuretic peptide(NT-proBNP)and cardiac function in patients with chronic heart failure(CHF).Method:Sixty-five patients with CHF treated in the Third People's Hospital of Jingzhou from January 2021 to January 2023 were selected as the study objects.They were divided into control group(32 cases)and observation group(33 cases)according to random drawing method.The control group was given Valsartan Tablets,and the observation group was given Sarcubatril Valsartan Sodium Tablets.Laboratory indexes,quality of life and cardiac function were compared between the two groups before treatment and 6 months after treatment.Result:After 6 months of treatment,the levels of AngⅡ,ALD and NT-proBNP in both groups were decreased,and the levels of AngⅡ,ALD and NT-proBNP in the observation group were lower than those in the control group,the differences were statistically significant(P<0.05).After 6 months of treatment,left ventricular ejection fraction(LVEF)increased,and left ventricular systolic diameter(LVESD)and left ventricular diastolic diameter(LVEDD)decreased in both groups.LVEF in observation group was significantly higher than that in control group,while LVESD and LVEDD were significantly lower than those in control group,the differences were statistically significant(P<0.05).After 6 months of treatment,the physical,emotional and other scores of both groups decreased,and the physical,emotional and other scores of the observation group were lower than those of the control group,the differences were statistically significant(P<0.05).Conclusion:In the treatment of CHF patients,Sacubactril Valsartan can reduce the levels of AngⅡ,ALD and NT-proBNP,reduce cardiac load,improve cardiac function and promote the improvement of quality of life.
作者
钟晶晶
许海涛
陈小翠
ZHONG Jingjing;XU Haitao;CHEN Xiaocui(The Third People's Hospital of Jingzhou,Jingzhou 434000,China;不详)
出处
《中外医学研究》
2024年第10期57-60,共4页
CHINESE AND FOREIGN MEDICAL RESEARCH
